Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti-inflammatory drug presented as an oral tablet for oral use. It is indicated for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and other acute pain conditions.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Movalis, a meloxicam‑based NSAID, acts on inflammatory pathways to manage several musculoskeletal disorders.

Osteoarthritis: reduces joint pain and swelling, improving mobility. Rheumatoid arthritis: alleviates chronic inflammation and joint damage. Ankylosing spondylitis: eases spinal pain and stiffness. Acute pain: provides rapid relief for short‑term painful episodes.

Common Side Effects: - Gastrointestinal discomfort such as dyspepsia or nausea. - Headache or dizziness. - Mild elevation of liver enzymes. - Edema or fluid retention. - Skin rash or pruritus.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe hepatic injury. - Renal impairment or failure. - Cardiovascular events such as myocardial infarction. - Severe skin reactions like Stevens‑Johnson syndrome. - Anaphylaxis or other hypersensitivity reactions.

Before initiating therapy, consider the following precautions: - Assess renal and hepatic function: adjust use if impairment is present. - Evaluate cardiovascular risk: use cautiously in patients with heart disease. - Monitor for gastrointestinal ulceration, especially in high‑risk individuals. - Avoid use in patients with known hypersensitivity to meloxicam or other NSAIDs. - Use during pregnancy only if clearly needed; category C indicates risk cannot be ruled out. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Meloxicam may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): elevated bleeding potential.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may enhance nephrotoxic effects. - Lithium: meloxicam can raise lithium serum levels. - Methotrexate: potential for increased toxicity.